The DaMaGe Project — defeating DMG
We combine clinical realism with fearless innovation. Mission: accelerate practical options for children with H3 K27-altered DMG through clear updates, targeted funding, and open collaboration—without deviating from clinical protocols.
Goal: long‑term control with gentle, precise add‑ons when allowed—never off‑protocol.
Every donation helps unlock tangible options for children facing DMG: platform access (ICV, CED, FUS‑BBB), advanced imaging (FET/FDOPA‑PET), and secure data sharing. Quarterly transparency reports show raised → deployed → results.
Power a specific milestone (biomarker test, imaging session, data curation).
Donate onceProvide compute, reagents, travel support, or clinical partnerships.
Partner with usWe do not provide medical advice. Treatment decisions rest with the clinical team. Donations are processed via trusted providers; tax deductibility depends on jurisdiction.
Audacious yet plausible concepts rooted in real technologies—ICV access, CED, focused‑ultrasound BBB windows, CAR‑T, RNA delivery—so clinicians and researchers can spot collaboration opportunities early.
We publish when our AI master‑agent flags qualified, canonical signals (new data, trial status changes, protocol amendments, regulatory updates). Each item cites one canonical source and marks EU/Nordic recruiting where relevant.
A rare, aggressive brain tumor arising in midline structures. Many DMGs carry H3 K27‑altered histone variants that reprogram gene regulation.
Infiltration of vital structures, protection by the BBB, and resistance to standard therapies.
Radiotherapy and protocol‑guided systemic options; trials are essential. Platform approaches (ICV, CED, FUS‑BBB) are explored within studies.
Targeted epigenetic therapies, PI3K/mTOR modulation in selected profiles, intraventricular CAR‑T, radiotheranostics, RNA delivery—mostly in trials.
No. We share clear information and fund enabling platforms. Treatment choices rest with the clinical team.
We fund practical enablers: access devices (ICV), delivery planning (CED/FUS), imaging, and data infrastructure.
We didn’t choose DMG—DMG chose us. Building this project is how we stay constructive: sharing what we learn, funding what moves the needle, and inviting collaborators to turn bold ideas into careful action. This is not medical advice; it’s a commitment to clarity and momentum for every child like our son.
Pairing protocol‑aligned care with platform readiness: if a pivot is needed later, there is no wasted time—only prepared options.
We accelerate practical options for children with DMG by pairing a realistic clinical backbone with future‑ready delivery platforms—ICV, CED, FUS‑BBB—and by boosting innovation with AI. We respect clinical protocols; we prepare so that, if a pivot is needed, no time is lost.
We welcome collaboration and questions from clinicians, researchers, foundations, and the community.
Medical disclaimer: Content is informational and not medical advice.
The DaMaGe Project